We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.629 | 1.62 | 1.638 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.98M | -0.0035 | -4.69 | 18.73M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/1/2020 09:55 | Hemo collaborates with two Nasdaq pharma CDX-ANTI BODIES AND CAR-T their mouse models outlive other pharma humanised mice as they die within a six week time frame, so there is a need for Hemo mice for longer term testing with pharma hence the interest, watch this space for a major update as the doors open to Hemogenyx. PR will be on the forefront in 2020 as presently it is woeful- Lilly are not involved with CAR-T there is a third Global pharma involved watch for that update. All in all a very exciting news rich period for Hemogenyx and long suffering shareholders - small free float difficult to buy in quantity as we have seen with the latest 30% rise. | shukan | |
17/1/2020 13:13 | "In a presentation to investors this week, Lilly Chief Executive David Ricks said most of its deals will be in the cancer space, but that other therapeutic areas remain of strong interest as well. While the company is still looking at late-stage assets, Smiley said the most opportunity for shareholders is in drugs in earlier stages of development. Deals could include licensing agreements, outright acquisitions, or other structures, he added." I pretty sure lilly are the globalco we're in development with.too many hints.... | purple11 | |
16/1/2020 19:18 | Vladislav Sandler @vmsandler It feels that #JPM2020 and it’s satellite #BiotechShowcase were the most productive for smaller agile companies looking for deals and partners. I am looking to 2020 with a lot of optimism and anticipation! | purple11 | |
16/1/2020 09:18 | you wont be seeing iamgreat here again.complete nutjob | purple11 | |
16/1/2020 09:12 | Told you people yesterday to book those profits But didn't listen Now down it goes like mph | iamgreat1 | |
16/1/2020 09:09 | Spot on Purple. NFX was around 2p for like 2 years and then it jumped like X4. Let’s see update about JPM conference. | marie1980 | |
16/1/2020 08:55 | I agree this is not the time to be losing your holding.we are moving into the interesting period now. expecting an NFX type move later in the year.happy to wait for it.gl | purple11 | |
16/1/2020 08:49 | There's a stacks of news to come this year and it will be transformational | tsmith2 | |
16/1/2020 08:46 | interesting post,the big gains lie ahead. scaramouche1941 15 Jan '20 - 21:03 - 3485 of 3486 0 1 0 As far as I know a normal progression in the drug development is 1. Target identification, 2. Target validation, 3. Molecule (antibody discovery, cell construction etc)design, 4. in vitro efficacy, 5. in vivo efficacy, 6. IND-enabling studies, 7. IND, 8. Clinical trials It looks like Hemo went to IND enabling studies with their antibody and now they are repeating the same with CAR T. I am impressed! All this for the money they raised when listed two years ago?!? This is crazy | purple11 | |
15/1/2020 19:46 | That should read ..... pointless deramping/bashing here.... | delano1967 | |
15/1/2020 19:43 | Remember this is not your normal PLC, it’s a team of scientists/miracle workers. That’s what makes this a share for only true investors that understand that you can own 1,000’s of shares now that could be worth £1,000’s in years to come. Pointless dreaming here... move on! GLA to true understanding investors in this story. | delano1967 | |
15/1/2020 19:25 | Weren't you going to buy when it went down to low 2's....but never did...I can see why you are annoyed.. Go back to CTEA forum..they miss you there...we don't... | johntopdog | |
15/1/2020 19:23 | Iamgreat1 aka @thelongergame aka ZM19 on LSE Aka jammydodger (stopped posting on 6th December set up iamgreat1 on 6th December and ZM19 on LSE 8th December Deramps under one name pumps on other names | texaschaser | |
15/1/2020 19:21 | Have I ever been wrong so far? Never. Look at all the sells piling in at the end of the day... | davevt | |
15/1/2020 18:55 | That's upset davevt today...3 posts...poor chap | johntopdog | |
15/1/2020 18:51 | Yet another 'in vitro' result... Investors are still waiting 2 years on for anything from the first in vitro results, if anything ever happens at all. Even today's result is years away from fruition. Next step from in vitro, is then testing in mice. Serious deja vu. Back down to sub 2s again it seems. | davevt | |
15/1/2020 18:24 | hopefully investors will use this thread.the other threads are getting ruined by idiots. | purple11 | |
15/1/2020 14:26 | Remember what happened to mph sell while u can before it goes back down again | iamgreat1 | |
15/1/2020 13:04 | This is going to a big big winner | tsmith2 | |
06/1/2020 08:08 | At these levels we are near, if not at the bottom sp/mkt cap valuation. Imv any substantive news or progress should have a strong beneficial effect. Hopefully Vladik will net a few investors at the upcoming JPM conference, given the interest that he told us about earlier. | badger60 | |
06/1/2020 03:26 | This stock is illiquid. The company should be treated by investors as private with a long horizon. It is unclear why this company is listed in the first place. If Hemo achieved even 20% of what they promised the valuation would probably go up 10x or more. It is a long haul though. They will need a lot of money to go into clinical trials and beyond. Having said all this I keep buying as I do not see any other micro-biotech on LSE that is better positioned than Hemo. | scaramouche1941 | |
02/1/2020 15:38 | Interestingly over the past 5 trading sessions the share price bottomed at 1.5p, and has peaked at 1.98p.....currently trading at 1.925p mid quote. This represents a 20-25% share price appreciation from the lows which highlights the way in which it can also rapidly go up, despite the general painful share price decline that shareholders have witnessed over the past couple of months or so. The fundamentals are very strong with Hemogenyx and according to Dr. Sandler all is on track as anticipated. The JPM conference, promises to generate investment interest we have been told.......and so exciting times ahead in 2020, imo. | badger60 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions